Paradoxically, while DLBCL patients with PD-L1 amplification had inferior PFS upon frontline chemo-immunotherapy, in the R/R setting, PD-L1 alterations were associated with a response to PD-1-targeted therapy [526]. Here, CD274 is linked to diffuse large B-cell lymphoma.